SCHEMBL31685710

SCHEMBL31685710

CN1C(=O)C=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ MTOR P42345 2/20 0.42
▸ THPO P40225 2/20 0.42
▸ PMP22 Q01453 2/20 0.42
▸ THRB P10828 1/20 0.42
▸ MDM2 Q00987 1/20 0.42
▸ NCOA1 Q15788 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GMNN O75496 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ DNMT1 P26358 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ BLM P54132 1/20 0.42
▸ HBB P68871 1/20 0.42
▸ CDA P32320 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31685726 0.86 MEN1 (0.35) LMNASMN1; SMN2ALDH1A1MTORTHPO
SCHEMBL31685513 0.82 ADORA1 (0.42) ADORA1
SCHEMBL31685787 0.82 P2RY2 (0.47) SMN1; SMN2ADORA1
SCHEMBL31685730 0.78 LMNA (0.44) LMNASMN1; SMN2PMP22DNMT1BLM
SCHEMBL40870 0.72 LMNA (0.41) LMNASMN1; SMN2ALDH1A1MTORTHPO
SCHEMBL22577619 0.71 CDA (0.42) LMNAMTORTHRBMDM2NCOA1
SCHEMBL19464875 0.71 SLC5A2 (0.42) SLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL21283173 0.70 CDA (0.47) LMNAMTORTHRBMDM2NCOA1
SCHEMBL31685626 0.70 LMNA (0.50) LMNASMN1; SMN2ALDH1A1THRBTP53
SCHEMBL18343088 0.70 PYGM (0.52) LMNASMN1; SMN2ALDH1A1MTORTHPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE TEAM MEDICAL, LLC 2025-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE SYNCRIP, SNRPA, RNASE1 LMNA 240/4885SMN1; SMN2 261/4885ALDH1A1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback